← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
CERRONE GABRIELE M
10% Owner | Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001139306
Purchase history
- Companies traded
- 3
- Purchases · 12M
- 4
- Purchases · 24M
- 9
- Average purchase
- $32.1K
- Median purchase
- $32.6K
- Gross purchase value
- $289.2K
Companies: Accustem Sciences Inc. | OKYO Pharma Ltd | Tiziana Life Sciences Ltd
9 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-07 | OKYO Pharma Ltd | OKYO | Director | 10% Owner | $35.0K | Open filing |
| 2026-08-07 | OKYO Pharma Ltd | OKYO | Director | 10% Owner | $32.6K | Open filing |
| 2026-08-07 | Tiziana Life Sciences Ltd | TLSA | Director | 10% Owner | $16.6K | Open filing |
| 2026-08-07 | Tiziana Life Sciences Ltd | TLSA | Director | 10% Owner | $41.9K | Open filing |
| 2025-06-16 | Accustem Sciences Inc. | ACUT | Director | 10% Owner | $2.4K | Open filing |
| 2025-06-13 | Accustem Sciences Inc. | ACUT | Director | 10% Owner | $18.5K | Open filing |
| 2025-04-10 | Accustem Sciences Inc. | ACUT | Director | 10% Owner | $25.5K | Open filing |
| 2025-04-08 | Accustem Sciences Inc. | ACUT | Director | 10% Owner | $78.6K | Open filing |
| 2025-01-03 | Accustem Sciences Inc. | ACUT | Director | 10% Owner | $38.0K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 7Developing | 77.8% (7/9) | 42.9% (3/7) | -13.3% | -7.8% | -35.6% |
| 20D | 7Developing | 77.8% (7/9) | 42.9% (3/7) | -12.8% | -6.3% | -37.5% |
| 60D | 5Developing | 100.0% (5/5) | 100.0% (5/5) | +37.2% | +43.3% | +11.0% |
| 120D | 5Developing | 100.0% (5/5) | 60.0% (3/5) | +85.0% | +65.5% | -45.0% |
Research patterns
- First purchase in 12M
- 2/8
- Large purchase ≥ $100k
- 0/9
- Cluster buying · 15D
- 4/9
- Buying the dip
- 4/7
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.